fasudil has been researched along with Parkinsonian Disorders in 2 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, Y | 1 |
| Zhang, Q | 2 |
| Xi, J | 1 |
| Xiao, B | 1 |
| Li, Y | 1 |
| Ma, C | 1 |
| He, Q | 1 |
| Li, YH | 1 |
| Guo, SS | 1 |
| Wang, Y | 1 |
| Lin, W | 1 |
| Wang, J | 1 |
| Ma, CG | 1 |
| Xiao, BG | 1 |
2 other studies available for fasudil and Parkinsonian Disorders
| Article | Year |
|---|---|
Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2015 |
Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intranasal; alpha-Synuclein; Animals; | 2016 |